Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma Key PointsQuestionIs savolitinib monotherapy more effective than sunitinib monotherapy on progression-free survival (PFS) in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC)? FindingsIn this phase 3, open-label, randomized clinical multicenter study including 60 patients with MET-driven PRCC, the primary end point was PFS. Although study enrollment was closed early, PFS was not statistically different for patients who received savolitinib or sunitinib, and the safety profile was superior with savolitinib. MeaningFurther investigation of savolitinib as a treatment option for MET-driven PRCC is warranted. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/efficacy-of-savolitinib-vs-sunitinib-in-patients-with-met-driven-Q8aq5tS9P3
Publisher
American Medical Association
Copyright
Copyright 2020 Choueiri TK et al. JAMA Oncology.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2218
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs savolitinib monotherapy more effective than sunitinib monotherapy on progression-free survival (PFS) in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC)? FindingsIn this phase 3, open-label, randomized clinical multicenter study including 60 patients with MET-driven PRCC, the primary end point was PFS. Although study enrollment was closed early, PFS was not statistically different for patients who received savolitinib or sunitinib, and the safety profile was superior with savolitinib. MeaningFurther investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 29, 2020

References